Traded Aug 14 – Aug 17, 2026 · largest single transaction ~$101K
Show all 2 transactions
Aug 14, 2026~$101K · 20K sh @ $5.06
DetailsOfficial recordAug 17, 2026~$25K · 5,000 sh @ $4.91
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VRCA · NASDAQ · Pharmaceutical Preparations
Verrica Pharmaceuticals (VRCA) · oqro.io/stocks/VRCA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.74−0.145 (−5.03%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
14 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Aug 14 – Aug 17, 2026 · largest single transaction ~$101K
Aug 14, 2026~$101K · 20K sh @ $5.06
DetailsOfficial recordAug 17, 2026~$25K · 5,000 sh @ $4.91
DetailsOfficial recordInsider buying
4 insiders in a week, 5th time since 2018Traded Aug 18 · filed the same day
Since the trade −41.5% · S&P 500 −10.1% · to Nov 20
Bought 49% below the 52-week high, RSI 35, 24% under its 200-day average, 24 points behind the S&P 500 over 3 months
Insider buying
3 insiders in a week, 6th time since 2018Traded Aug 17 · filed 1 day later
Since the trade −44.0% · S&P 500 −10.7% · to Nov 20
Bought 46% below the 52-week high, RSI 38, 21% under its 200-day average, 27 points behind the S&P 500 over 3 months
Traded Aug 17 – Aug 18, 2026 · largest single transaction ~$21K
Aug 17, 2026~$21K · 4,200 sh @ $4.91
DetailsOfficial recordTraded Nov 25, 2025 · largest single transaction ~$11.7M
Nov 25, 2025~$11.7M · 2.75M sh @ $4.24
DetailsOfficial recordInsider buying
5 insiders in a week, 3rd time since 2018Traded Nov 25, 2025 · filed 1 day later
Since the trade −46.5% · S&P 500 +2.2% · to Nov 20
Bought 60% below the 52-week high, RSI 67, 6% under its 200-day average, 14 points behind the S&P 500 over 3 months
Insider buying
5 insiders in a week, 3rd time since 2018Traded Nov 25, 2025 · filed 1 day later
Since the trade −46.5% · S&P 500 +2.2% · to Nov 20
Bought 60% below the 52-week high, RSI 67, 6% under its 200-day average, 14 points behind the S&P 500 over 3 months
Insider buying
5 insiders in a week, 3rd time since 2018Traded Nov 25, 2025 · filed 1 day later
Since the trade −46.5% · S&P 500 +2.2% · to Nov 20
Bought 60% below the 52-week high, RSI 67, 6% under its 200-day average, 14 points behind the S&P 500 over 3 months
Insider buying
5 insiders in a week, 3rd time since 2018Traded Nov 25, 2025 · filed 1 day later
Since the trade −46.5% · S&P 500 +2.2% · to Nov 20
Bought 60% below the 52-week high, RSI 67, 6% under its 200-day average, 14 points behind the S&P 500 over 3 months
Christopher G. Hayes (CHIEF LEGAL OFFICER) sold ~$2.8K of Verrica Pharmaceuticals
Automatic saleVerrica Pharmaceuticals's Chief Operating Officer paid $30K out of pocket for Verrica Pharmaceuticals shares. 3 other people at Verrica Pharmaceuticals bought some too, in the same month. It was the first purchase in 9 months.
Aug 18, 2026~$10K · 2,030 sh @ $4.92
DetailsOfficial recordNov 25, 2025~$5.84M · 1.38M sh @ $4.24
DetailsOfficial recordThe CEO of Verrica Pharmaceuticals paid $400K out of pocket for Verrica Pharmaceuticals shares. 4 other people at Verrica Pharmaceuticals bought some too, in the same month. Shares held went up 107% with this purchase.
Verrica Pharmaceuticals's Chief Operating Officer paid $42K out of pocket for Verrica Pharmaceuticals shares. 4 other people at Verrica Pharmaceuticals bought some too, in the same month. Shares held went up 91% with this purchase.
6 open-market purchases and 0 open-market sales by insiders of VRCA between Feb 9, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 12, 2026. The data provider lists the next release for Mar 8, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 12, 2026 | None | None | None |
| Aug 6, 2026 | None | None | 6 purchases |
| May 12, 2026 | None | None | None |
| Mar 11, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies